Nova23041, a formulation for the treatment of dry eye symptoms, is a preservative-free oil-in-water emulsion resulting from Novasorb patented technology.
Novagali claims the Novasorb’s technological platform enables the product to be spread in an optimal, uniform and comfortable way across the entire ocular surface.
Nova23041 has been marketed since 2008 under the brand name Cationorm, a brand that belongs to Novagali Pharma.
The product will be marketed in the US and Canada under the brand name Retaine MGD Ophthalmic Emulsion.
OCuSOFT will become the exclusive promoter.
Ardeo Health president and CEO Robert ‘Bob’ Sykora said patients suffering from dry eye will now have an alternative to expensive prescription (Rx) therapies.
Novagali Pharma chairman Jerome Martinez said OCuSOFT’s teams will no doubt make Nova23041’s launch in the US and Canada a success that will enable them to extend the distribution of their formulation for treating dry eye symptoms around the world.